Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface.
Journal article
Ni T. et al, (2023), iScience, 26
Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.
Journal article
Port JR. et al, (2023), Nature communications, 14
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Journal article
Jenkin D. et al, (2023), The Lancet Infectious Diseases, 23, 956 - 964
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Journal article
Kaplonek P. et al, (2023), Nature immunology
COVID-19 vaccines and the pandemic: lessons learnt for other neglected diseases and future threats.
Journal article
Hotez PJ. et al, (2023), BMJ global health, 8
Factors, enablers and challenges for COVID-19 vaccine development.
Journal article
Excler J-L. et al, (2023), BMJ global health, 8
Vaccine access, equity and justice: COVID-19 vaccines and vaccination.
Journal article
Privor-Dumm L. et al, (2023), BMJ global health, 8
ChAdOx1 COVID vaccines express RBD open prefusion SARS-CoV-2 spikes on the cell surface
Preprint
Zhang P. et al, (2023)
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Journal article
Koen AL. et al, (2023), Vaccine, 41, 3486 - 3492
Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model
Journal article
Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials
Journal article
Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Journal article
Madhi SA. et al, (2023), The Lancet. Infectious diseases, 23, 295 - 306
Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs.
Journal article
Vatzia E. et al, (2023), NPJ Vaccines, 8
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
Journal article
Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209
T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.
Journal article
McMahon WC. et al, (2023), AIDS (London, England), 37, 105 - 112
ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys.
Journal article
van Doremalen N. et al, (2022), NPJ vaccines, 7
Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.
Journal article
Cable J. et al, (2022), Annals of the New York Academy of Sciences
Production of a high purity, C‐tagged hepatitis B surface antigen fusion protein VLP vaccine for malaria expressed in Pichia pastoris under cGMP conditions
Journal article
Mukhopadhyay E. et al, (2022), Biotechnology and Bioengineering, 119, 2784 - 2793
ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.
Journal article
van Doremalen N. et al, (2022), Nature communications, 13
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Journal article
Alharbi NK. et al, (2022), Vaccines, 10